Posted by Michael Wonder on 26 Jun 2017
Has the interim report considered long term supply chain impacts?
23 June 2017 - Medicines Australia welcomes the release of the Interim Report of Pharmacy Review but has concerns about some proposals that could damage the National Medicines Policy and have negative impacts for the manufacturers of medicines, distributors, community pharmacies and patients.
Medicines Australia Chief Executive Milton Catelin said, “The innovative pharmaceutical industry believes it is important to always be looking to improve processes that relate to the supply of medicines to Australians, however, any change must be done with the full support and confidence of the companies that make the medicines, the wholesale distributors and the pharmacists who dispense them.”
“A number of ideas put forward in the interim report are of real concern to Medicines Australia as they are either ineffective, could potentially diminish medicine quality or lead to potential medicines shortages for patients,” said Mr Catelin.
